LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

Inicio・Lista de Acciones・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Abierto

1.38 3.76

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.32

Máximo

1.3900000000000001

Métricas clave
By Trading Economics
Ingresos	17M -26M
Empleados	171
EBITDA	19M -23M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+87.97% upside

Dividendos
By Dow Jones
Próximas Ganancias	12 mar 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-21M 81M
Apertura anterior	-2.38
Cierre anterior	1.38

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.43 / 1.6 Soporte y Resistencia

Pliant Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 mar 2026, 19:18 UTC

Principales Movimientos del Mercado

Stryker Shares Down After Cyberattack Tied to Iran-Linked Group

11 mar 2026, 23:54 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

11 mar 2026, 23:54 UTC

Charlas de Mercado

Nikkei May Decline on Energy Costs Concerns -- Market Talk

11 mar 2026, 23:51 UTC

Charlas de Mercado

Gold Falls as Rising Oil Prices Spur Inflation Worries -- Market Talk

11 mar 2026, 23:41 UTC

Charlas de Mercado

REA Bull Sees Potential Upside to Yield Guidance -- Market Talk

11 mar 2026, 23:37 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Rise Amid Ongoing Middle East Conflict -- Market Talk

11 mar 2026, 23:17 UTC

Noticias de Eventos Importantes

Front-Month WTI Crude Oil Futures Rise 5.5% to $92.05/bbl

11 mar 2026, 23:17 UTC

Noticias de Eventos Importantes

Front-Month Crude Oil Futures Rise Amid Ongoing Middle East Conflict

11 mar 2026, 22:29 UTC

Charlas de Mercado

Australia Shares Set to Fall in Early Trade -- Market Talk

11 mar 2026, 21:47 UTC

Ganancias

Liontown Resources: Market Tailwinds Strengthening Outlook

11 mar 2026, 21:46 UTC

Ganancias

Liontown Resources: 4 Mln Ton Per Annum Expansion Study Underway

11 mar 2026, 21:45 UTC

Ganancias

Liontown Resources Says FY26 Guidance Unchanged

11 mar 2026, 21:45 UTC

Ganancias

Liontown Resources 1H Unit Operating Costs A$985/Ton

11 mar 2026, 21:44 UTC

Ganancias

Liontown Resources 1H Underlying Ebitda Loss A$7.7 Million

11 mar 2026, 21:43 UTC

Ganancias

Liontown Resources 1H Revenue A$207.5 Million

11 mar 2026, 21:43 UTC

Ganancias

Liontown Resources 1H Net Loss A$184 Million

11 mar 2026, 21:12 UTC

Adquisiciones, fusiones, absorciones

Netflix Rival Strikes Deal With Google in Battle for AI Content -- Barrons.com

11 mar 2026, 21:10 UTC

Ganancias

Vista Gold FY25 Loss $7.5M >VGZ

11 mar 2026, 21:10 UTC

Ganancias

Vista Gold FY25 Loss/Shr 6c >VGZ

11 mar 2026, 20:50 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

11 mar 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

11 mar 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Papa John's Draws Fresh Takeover Interest -- 2nd Update

11 mar 2026, 20:26 UTC

Ganancias

These Stocks Are Today's Movers: Oracle, UniFirst, Fair Isaac, Nebius, AeroVironment, Campbell's, and More -- Barrons.com

11 mar 2026, 20:19 UTC

Noticias de Eventos Importantes

The Strait of Hormuz Could Take Weeks -- Even Months -- to Reopen, Military Experts Say -- Barrons.com

11 mar 2026, 20:15 UTC

Ganancias

This Physical AI Stock Jumped on Earnings. The Robots Are Coming. -- Barrons.com

11 mar 2026, 20:12 UTC

Noticias de Eventos Importantes

Stock Market Today: Oil Prices Push Higher Despite IEA Oil Release Headline -- WSJ

11 mar 2026, 19:31 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Oil Futures Gain Despite IEA's Planned Release of Reserves -- Market Talk

11 mar 2026, 19:01 UTC

Charlas de Mercado

Noticias de Eventos Importantes

U.S. Natural Gas Gains With Middle East Conflict in View -- Market Talk

11 mar 2026, 18:59 UTC

Adquisiciones, fusiones, absorciones

Berkshire's Deal for Occidental Chemicals Unit Is a Winner as Chemical Stocks Surge -- Barrons.com

11 mar 2026, 18:43 UTC

Noticias de Eventos Importantes

Chubb Named Lead Insurer for U.S. Plan to Protect Oil Tankers in Strait of Hormuz -- Barrons.com

Comparación entre iguales

Cambio de precio

Pliant Therapeutics Inc previsión

Precio Objetivo

By TipRanks

87.97% repunte

Estimación a 12 Meses

Media 2.5 USD 87.97%

Máximo 3 USD

Mínimo 2 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

Comprar

Mantener

Vender

De acuerdo con 3 analistas que ofrecen calificaciones bursátiles a para Pliant Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.43 / 1.6Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.